Page 6 - Dr Reddy's Laboratories

Dr Reddy's denied approval for Phase 3 trials of Sputnik Light vaccine

After launching Sputnik V, Russia had introduced a new single-dose vaccine called Sputnik Light in May

DRL launches DRDO drug 2-DG to treat moderate to severe Covid patients

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's

Wockhardt's growth tonic: Covid vaccines add a third prong to biz strategy

In India, Wockhardt aims to make 2 billion doses of Covid-19 vaccines within the next one or two years but has not disclosed the identity of the tie-ups

Dr Reddy's recalls 2,980 bottles of cholesterol lowering drug in US

Drug major Dr Reddy's Laboratories is recalling 2,980 bottles of Atorvastatin Calcium tablets in the US due to quality issues.

BMC rejects all nine vaccine bids, in talk with Dr Reddy's for Sputnik jab

DRL has shown willingness to provide a limited quantity of the Russian shot to the civic body in June under a pilot programme

Snowman Logistics partners with Dr Reddy's for Sputnik vaccine across India

Snowman said it has entered in a strategic partnership with Dr Reddy's to provide end-to-end logistics solutions for delivery of the two-dose Sputnik Covid-19 vaccine across India

2-DG drug for Covid-19 treatment: Here're the benefits and concerns

The idea behind using 2-DG in Covid-19 is that along with other anti-virals, it can help prevent replication of the Sars-CoV-2 virus in inflamed lung cells of Covid-19 patients

Covid-19: Dr Reddy's rolls out Sputnik V in India at Rs 995 per dose

The imported doses of the vaccine are priced at a maximum retail price of Rs 948 plus 5 percent GST per dose, with the possibility of a lower price point when local supply begins, says DRL

Dr Reddy's consolidated net dips 28% to Rs 554 crore in March quarter

Dr Reddy's Laboratories on Friday reported a consolidated net profit of Rs 554 crore for the quarter ended March, down 28 per cent from Rs 764 crore in the same period of the previous fiscal.The company said selling, general and administrative (SG & A) expenses went up by 17 per cent to Rs 1,430 crore due to incremental costs after the integration of Wockhardt's acquired divisions and increased freight expenses.Consolidated revenues grew 7 per cent year-on-year to Rs 4,728 crore while R & D expenses comprised 8.7 per cent of revenues at Rs 409 crore.Earnings before interest, taxes, depreciation and amortisation (EBITDA) were up 13 per cent year-on-year during Q4 FY21 at Rs 1,133 crore.For the entire year (FY21), profit after tax totalled Rs 1,915 crore on revenues of Rs 18,972 crore.Co-Chairman and MD G V Prasad said the company continued to grow across all businesses, enhanced productivity and strengthened development pipeline."We are prioritising our efforts to launch ...

Covid-19: Govt waives import duty on Remdesivir injection, raw materials

Given the shortage of supplies, the Union government last week banned the export of Remdesivir

Dr Reddy's to also use govt cold chain infra for Sputnik V distribution

The vaccine would be transported in frozen form by air and road

Dr Reddy's stock sheds 4% as Sputnik V pricing, competition weigh

Access to the private market, international sales are other factors that will impact margins

India gets third Covid-19 vaccine as SEC clears Russia's Sputnik V

Final nod from DCGI soon, jab likely at $3/dose

Dr Reddys surges 5% as Sputnik V gets expert panel nod for emergency use

This is the third vaccine approved by India, after Covishield and Covaxin.

India drug regulator asks Dr. Reddy's for more data on Sputnik V vaccine

An expert panel of India's drug regulator sought additional data from drugmaker Dr Reddy's on its Sputnik V Covid-19 vaccine trial, in its second such request after an initial evaluation in February

Expert panel defers decision on Sputnik V Covid-19 vaccine, wants more data

Details of -25°C cold chain plan sought

No Sputnik V approval yet, SEC asks Dr Reddy's for more data on vax

The Subject Expert Committee (SEC) of the Indian drug regulator, tasked with vetting Covid-19 vaccine proposals, sought additional data on Russian Covid-19 vaccine 'Sputnik V'

Wait for Sputnik V Covid-19 vaccine may get over in a few weeks: DRL

"We expect to get the approval in the next few weeks," said Deepak Sapra, CEO, API and pharmaceutical services, Dr Reddy's Laboratories (DRL)

Dr Reddy's expects Covid vaccine to get nod from India in next few weeks

Pharma major Dr Reddy's Laboratories expects the Russian coronavirus vaccine Sputnik V to get approval from the Indian regulator in the next few weeks, a company official has said

Stelis Biopharma to make 200 mn doses of Russia's Sputnik V Covid vaccine

Stelis will commence supplies from September quarter of 2021 and will also continue to work with RDIF to provide additional supply volumes beyond the initial agreement